Compound to Enhance Immune Stimulation

Gerald Fink and Ifat Rubin-Bejerano

Monoclonal antibodies, currently a means of enabling speedier and more economic drug development, also have enormous untapped potential for use in more direct therapeutic applications for a wide range of diseases and conditions. However, many monoclonal antibodies currently fail to elicit an effective immune response, despite great specificity to target cells. This project is developing a compound to stimulate a more powerful immune response to specific monoclonal antibodies, potentially enabling development of effective new disease therapies.

The technology from this project was spun out into a startup company, ImmuneXcite.